Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

OSU-2S, a Novel PKC Activator, Mediates PKC Dependent Cell Death, Differentiation and Cell Cycle Arrest in Acute Myeloid Leukemia

Swagata Goswami, MS, Rajeswaran Mani, DVM,PhD, Xiaokui Mo, PhD MAS, Pearlly S. Yan, PhD, Michael B Broe, PhD, Ralf Bundschuh, PhD, Larry State Beaver, Kevan Zapolnik, BS, Zhiliang Xie, Donna Bucci, David M. Lucas, PhD, Allison R. Walker, MD MPH, Alice S. Mims, MD MSCR, Rebecca B. Klisovic, MD, Ching-Shih Chen, PhD, John C. Byrd, MD, Mitch A. Phelps, PhD, Sumithira Vasu, MDMBBS, Natarajan Muthusamy, DVM,PhD

Blood (2017) 130 (Supplement 1): 1247.

https://doi.org/10.1182/blood.V130.Suppl_1.1247.1247

Published: 2017

Journal Articles

CD33 Targeted Immunoliposomal Delivery of OSU-2S, a Non-Immunosuppressive FTY720 Derivative, Mediates Selective Cytotoxicity in Acute Myeloid Leukemia

Swagata Goswami, MS, Rajeswaran Mani, DVM PhD, Chi-Ling Chiang, MS, Frank W Frissora, M.S., Xiaokui Mo, PhD MAS, Zhiliang Xie, Donna Bucci, Amber Gordon, MLS, David M. Lucas, PhD, William Blum, MD, Alison R. Walker, MD MPH, Alice S. Mims, MD MSCR, Rebecca B Klisovic, MD, Ching-Shih Chen, PhD, Robert J Lee, PhD, John C. Byrd, MD, Mitch A. Phelps, PhD, Sumithira Vasu, MBBS, Natarajan Muthusamy, DVM, PhD

Blood (2016) 128 (22): 2748.

https://doi.org/10.1182/blood.V128.22.2748.2748

Published: 2016

Journal Articles

BRAF V600E Induces ABCB1/P-Glycoprotein Expression and Drug Resistance in B-Cells Via AP-1 Activation

Yo-Ting Tsai, MS, Gerard Lozanski, MD, Amy M. Lehman, MAS, Ellen Sass, Erin K. Hertlein, PhD, Santosh Salunke, Ching-Shih Chen, PhD, Michael R. Grever, MD, John C. Byrd, MD, David M. Lucas, PhD

Blood (2015) 126 (23): 2477.

https://doi.org/10.1182/blood.V126.23.2477.2477

Published: 2015

Journal Articles

OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells

Ta-Ming Liu, Yonghua Ling, Jennifer A. Woyach, Kyle Beckwith, Yuh-Ying Yeh, Erin Hertlein, Xiaoli Zhang, Amy Lehman, Farrukh Awan, Jeffrey A. Jones, Leslie A. Andritsos, Kami Maddocks, Jessica MacMurray, Santosh B. Salunke, Ching-Shih Chen, Mitch A. Phelps, John C. Byrd, Amy J. Johnson

Blood (2015) 125 (2): 284–295.

https://doi.org/10.1182/blood-2014-06-583518

Published: 2015

Includes: Supplemental data

Journal Articles

PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL

Dalia El-Gamal, Katie Williams, Taylor D. LaFollette, Matthew Cannon, James S. Blachly, Yiming Zhong, Jennifer A. Woyach, Erich Williams, Farrukh T. Awan, Jeffrey Jones, Leslie Andritsos, Kami Maddocks, Chia-Hsien Wu, Ching-Shih Chen, Amy Lehman, Xiaoli Zhang, Rosa Lapalombella, John C. Byrd

Blood (2014) 124 (9): 1481–1491.

https://doi.org/10.1182/blood-2014-05-574830

Published: 2014

Includes: Supplemental data

Journal Articles

OSU-T315, An Integrin-Linked Kinase (ILK) Inhibitor, Induces Apoptosis By Targeting B Cell Receptor and CD49d Mediated AKT/ERK Activation In Chronic Lymphocytic Leukemia Cells

Ta-Ming Liu, YongHua Ling, Mitch A. Phelps, PhD, Jennifer A. Woyach, MD, Erin K Hertlein, PhD, William H. Towns, Jessica MacMurray, Santosh B. Salunke, PhD, Ching-Shih Chen, PhD, John C. Byrd, MD, Amy J. Johnson, PhD

Blood (2013) 122 (21): 2523.

https://doi.org/10.1182/blood.V122.21.2523.2523

Published: 2013

Journal Articles

Tumor Antigen ROR1 Targeted Delivery Of FTY720 Derivative OSU-2S Prolongs Survival In ROR1 Engineered Mouse Model Of Chronic Lymphocytic Leukemia

Rajeswaran Mani, DVM, Yicheng Mao, PhD, Frank W Frissora, M.S., Chi-ling Chiang, Jiang Wang, Yuan Zhao, Yun Wu, Bo Yu, Ph.D., Ribai Yan, Xiaokui Mo, PhD, Sivasubramanian Baskar, PhD, Christoph Rader, Ph.D., Mitch A. Phelps, PhD, Robert J. Lee, Ph.D, Ching-Shih Chen, PhD, James Lee, PhD, John C. Byrd, MD, Natarajan Muthusamy, DVM, Ph.D

Blood (2013) 122 (21): 4168.

https://doi.org/10.1182/blood.V122.21.4168.4168

Published: 2013

Journal Articles

Increased Expression Of IL-15 Promotes Cutaneous T-Cell Lymphomagenesis Via The Upregulation Of Histone Deacetylases: Evidence For Successful Preclinical Targeting

Anjali Mishra, Ph.D., Krista M.D. La Perle, DVM, PhD, Dipl. ACVP, Laura Sullivan, BS, Gregory H Sams, Douglas P Curphey, Kathleen McConnell, BS, Jun Qi, PhD, Henry K Wong, MD, PhD, Samuel K Kulp, PhD, Soledad Fernandez, PhD, James E Bradner, MD, Guido Marcucci, MD, Ching-Shih Chen, PhD, Pierluigi Porcu, MD, Michael A. Caligiuri, MD

Blood (2013) 122 (21): 1826.

https://doi.org/10.1182/blood.V122.21.1826.1826

Published: 2013

Journal Articles

PKC Inhibitor AEB071 Demonstrates Pre-Clinical Activity In Chronic Lymphocytic Leukemia

Dalia ElGamal, PhD, Yiming Zhong, PhD, Katie Williams, MS, Chia-Hsien Wu, Ching-Shih Chen, PhD, Rosa Lapalombella, PhD, John C. Byrd, MD

Blood (2013) 122 (21): 4187.

https://doi.org/10.1182/blood.V122.21.4187.4187

Published: 2013

Journal Articles

FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death

Lapo Alinari, Emilia Mahoney, John Patton, Xiaoli Zhang, Lenguyen Huynh, Christian T. Earl, Rajeswaran Mani, Yicheng Mao, Bo Yu, Carl Quinion, William H. Towns, Ching-Shih Chen, David M. Goldenberg, Kristie A. Blum, John C. Byrd, Natarajan Muthusamy, Mette Prætorius-Ibba, Robert A. Baiocchi

Blood (2011) 118 (26): 6893–6903.

https://doi.org/10.1182/blood-2011-06-363879

Published: 2011

Includes: Multimedia, Supplemental data

Journal Articles

OSU-2S, A Novel FTY720 derivative, Mediates Cytotoxicity In Chronic Lymphocytic Leukemia Through PKC Dependent Modulation of SHP1 Tyrosine Phosphatase

Rajeswaran Mani, DVM, Frank W Frissora, M.S., Ching-Shih Chen, Ph.D, John C. Byrd, MD, Natarajan Muthusamy, DVM, Ph.D

Blood (2011) 118 (21): 2499.

https://doi.org/10.1182/blood.V118.21.2499.2499

Published: 2011

Journal Articles

FTY720 Increases CD74 Expression and Sensitizes Mantle Cell Lymphoma Cells to Milatuzumab-Mediated Cell Death

Lapo Alinari, MD., Ph.D., Emilia Mahoney, MD, PhD, John T. Patton, Xiaoli Zhang, PhD, MS, Lenguyen Huynh, Christian Tyler Earl, Rajeswaran Mani, DVM, Yicheng Mao, Bo Yu, Ph.D., William H. Towns, Ching-Shih Chen, Ph.D, David M. Goldenberg, Kristie A. Blum, MD, John C. Byrd, MD, Natarajan Muthusamy, DVM, Ph.D, Mette Ibba, PhD, Robert A. Baiocchi, M.D., Ph.D.

Blood (2011) 118 (21): 600.

https://doi.org/10.1182/blood.V118.21.600.600

Published: 2011

Journal Articles

BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment

Blood (2010) 116 (21): 515.

https://doi.org/10.1182/blood.V116.21.515.515

Published: 2010

Journal Articles

Pharmacologic Restoration of PP2A Activity and Interference with the SET-PP2A Interplay by FTY720 and Its Non-Immunosuppressive Derivative as a Novel and Efficient Therapy for Ph-Negative Myeloproliferative Disorders

Joshua J Oaks, A. Mukhopadhyay, Ramasamy Santhanam, S. A Saddoughi, Christopher Walker, Paolo Neviani, Jason G Harb, Y. Ma, Srdan Verstovsek, MD, PhD, Guido Marcucci, MD, Roger Briesewitz, Robert Bittman, Ching-Shih Chen, Alfonso Quintas-Cardama, MD, Besim Ogretmen, Danilo Perrotti, MD, PhD

Blood (2010) 116 (21): 775.

https://doi.org/10.1182/blood.V116.21.775.775

Published: 2010

Journal Articles

PP2A Activating Drugs (PAD): Anti-Leukemic and Non-Toxic Activity of Two Novel and Non-Immunosuppressive FTY720 Derivatives

Christopher Walker, B.S., Joshua J Oaks, B.S., Paolo Neviani, Ph.D, Jason G Harb, Ph.D., Ramasamy Santhanam, Ph.D, Y. Ma, Guido Marcucci, MD, James Van Brocklyn, Ph.D, Ching-Shih Chen, Ph.D, Robert Bittman, Ph.D, Danilo Perrotti, MD, PhD

Blood (2010) 116 (21): 2901.

https://doi.org/10.1182/blood.V116.21.2901.2901

Published: 2010

Journal Articles

AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit

Tzu-Yin Lin, Joelle Fenger, Sridhar Murahari, Misty D. Bear, Samuel K. Kulp, Dasheng Wang, Ching-Shih Chen, William C. Kisseberth, Cheryl A. London

Blood (2010) 115 (21): 4217–4225.

https://doi.org/10.1182/blood-2009-07-231985

Published: 2010

Journal Articles

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase–dependent pathway

Blood (2010) 115 (13): 2619–2629.

https://doi.org/10.1182/blood-2009-09-242438

Published: 2010

Includes: Supplemental data

Journal Articles

FTY720 but Not Its Immunosuppressive Phosphorylated Form FTY720-P Exerts Anti-Leukemic Activity towards Ph(+) and Ph(−) Myeloproliferative Disorders through Reactivation of the PP2A Tumor Suppressor.

Joshua Oaks, BS, Paolo Neviani, PhD, A. Mukhopadhyay, Ramasamy Santhanam, PhD, Y. Ma, Charlene Mao, Guido Marcucci, MD, Ching-Shih Chen, Jorge Cortes, MD, Michael A. Caligiuri, M.D., Peter Hokland, Sr., Claudia Huettner, PhD, Steffen Koschmieder, MD, Jose Cancelas, MD, PhD, Roger Briesewitz, PhD, Ravi Bhatia, MD, Denis-Claude Roy, MD, Besim Ogretmen, PhD, Danilo Perrotti, MD, PhD

Blood (2009) 114 (22): 3259.

https://doi.org/10.1182/blood.V114.22.3259.3259

Published: 2009

Journal Articles

FTY720 Demonstrates Promising in-Vitro and in-Vivo Pre-Clinical Activity by Down-Modulation of Cyclin D1 and Pakt in Mantle Cell Lymphoma.

Lapo Alinari, MD, Qing Liu, PhD, Ching-Shih Chen, PhD, Fengting Yan, MD, PhD, James T Dalton, PhD, Rosa Lapalombella, PhD, Xiaoli Zhang, PhD, Teresa Lin, BS, John C. Byrd, MD, Robert A. Baiocchi, MD, PhD, Natarajan Muthusamy, PhD

Blood (2009) 114 (22): 3728.

https://doi.org/10.1182/blood.V114.22.3728.3728

Published: 2009

Journal Articles

OSU-DY7, a Novel D -Tyrosinol Derivative, Mediates Cytotoxicity in Chronic Lymphocytic Leukemia and Lymphoblastic Lymphoma through p38 Mitogen-Activated Protein Kinase Pathway.

Li-Yuan Bai, MD, Yihui Ma, Samuel K Kulp, Shu-Huei Wang, PhD, Chang-Fang Chiu, MD, DMS, Frank Frissora, Xiaokui Mo, David Jarjoura, John C. Byrd, Ching-Shih Chen, Natarajan Muthusamy, DVM., PhD

Blood (2009) 114 (22): 3778.

https://doi.org/10.1182/blood.V114.22.3778.3778

Published: 2009

NARROW

OSU-2S, a Novel PKC Activator, Mediates PKC Dependent Cell Death, Differentiation and Cell Cycle Arrest in Acute Myeloid Leukemia

CD33 Targeted Immunoliposomal Delivery of OSU-2S, a Non-Immunosuppressive FTY720 Derivative, Mediates Selective Cytotoxicity in Acute Myeloid Leukemia

BRAF V600E Induces ABCB1/P-Glycoprotein Expression and Drug Resistance in B-Cells Via AP-1 Activation

OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells

PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL

OSU-T315, An Integrin-Linked Kinase (ILK) Inhibitor, Induces Apoptosis By Targeting B Cell Receptor and CD49d Mediated AKT/ERK Activation In Chronic Lymphocytic Leukemia Cells

Tumor Antigen ROR1 Targeted Delivery Of FTY720 Derivative OSU-2S Prolongs Survival In ROR1 Engineered Mouse Model Of Chronic Lymphocytic Leukemia

Increased Expression Of IL-15 Promotes Cutaneous T-Cell Lymphomagenesis Via The Upregulation Of Histone Deacetylases: Evidence For Successful Preclinical Targeting

PKC Inhibitor AEB071 Demonstrates Pre-Clinical Activity In Chronic Lymphocytic Leukemia

FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death

OSU-2S, A Novel FTY720 derivative, Mediates Cytotoxicity In Chronic Lymphocytic Leukemia Through PKC Dependent Modulation of SHP1 Tyrosine Phosphatase

FTY720 Increases CD74 Expression and Sensitizes Mantle Cell Lymphoma Cells to Milatuzumab-Mediated Cell Death

BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment

Pharmacologic Restoration of PP2A Activity and Interference with the SET-PP2A Interplay by FTY720 and Its Non-Immunosuppressive Derivative as a Novel and Efficient Therapy for Ph-Negative Myeloproliferative Disorders

PP2A Activating Drugs (PAD): Anti-Leukemic and Non-Toxic Activity of Two Novel and Non-Immunosuppressive FTY720 Derivatives

AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase–dependent pathway

FTY720 but Not Its Immunosuppressive Phosphorylated Form FTY720-P Exerts Anti-Leukemic Activity towards Ph(+) and Ph(−) Myeloproliferative Disorders through Reactivation of the PP2A Tumor Suppressor.

FTY720 Demonstrates Promising in-Vitro and in-Vivo Pre-Clinical Activity by Down-Modulation of Cyclin D1 and Pakt in Mantle Cell Lymphoma.

OSU-DY7, a Novel D -Tyrosinol Derivative, Mediates Cytotoxicity in Chronic Lymphocytic Leukemia and Lymphoblastic Lymphoma through p38 Mitogen-Activated Protein Kinase Pathway.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only